BIOMAT Database Logo BIOMAT Database Logo

Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. 2017

Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20993, USA.

Modeling and simulation approaches are increasingly being utilized in pediatric drug development. Physiologically based pharmacokinetic (PBPK) modeling offers an enhanced ability to predict age-related changes in pharmacokinetics in the pediatric population. In the current study, adult PBPK models were developed for the renally excreted drugs linezolid and emtricitabine. PBPK models were then utilized to predict pharmacokinetics in pediatric patients for various age groups from the oldest to the youngest patients in a stepwise approach. Pharmacokinetic predictions for these two drugs in the pediatric population, including infants and neonates, were within a twofold range of clinical observations. Based on this study, linezolid and emtricitabine pediatric PBPK models incorporating the ontogeny in renal maturation describe the pharmacokinetic differences between adult and pediatric populations, even though the contribution of renal clearance to the total clearance of two drugs was very different (30 % for linezolid vs. 86 % for emtricitabine). These results suggest that PBPK modeling may provide one option to help predict the pharmacokinetics of renally excreted drugs in neonates and infants.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D005544 Forecasting The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology. Futurology,Projections and Predictions,Future,Predictions and Projections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068679 Emtricitabine A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine,Coviracil,Emtriva,Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine
D000069349 Linezolid An oxazolidinone and acetamide derived ANTI-BACTERIAL AGENT and PROTEIN SYNTHESIS INHIBITOR that is used in the treatment of GRAM-POSITIVE BACTERIAL INFECTIONS of the skin and respiratory tract. Linezolide,N-((3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide,PNU-100766,U 100766,U-100766,Zyvox,100766, U,PNU 100766,PNU100766,U100766
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
March 2020, The Journal of antimicrobial chemotherapy,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically based pharmacokinetic prediction of telmisartan in human.
October 2014, Drug metabolism and disposition: the biological fate of chemicals,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach.
May 2022, Clinical pharmacokinetics,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives.
December 2023, Pharmaceutics,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
November 2021, Journal of clinical pharmacology,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
February 2020, Journal of clinical pharmacology,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants.
December 2021, Clinical pharmacokinetics,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling.
September 2023, Pharmaceutics,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates.
June 2020, Pharmaceutics,
Peng Duan, and Jeffrey W Fisher, and Kenta Yoshida, and Lei Zhang, and Gilbert J Burckart, and Jian Wang
Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK.
January 2022, Frontiers in pharmacology,
Copied contents to your clipboard!